RTRX - Retrophin, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
29.22
+0.26 (+0.90%)
At close: 4:00PM EDT

29.22 0.00 (0.00%)
After hours: 5:26PM EDT

Stock chart is not supported by your current browser
Previous Close28.96
Open28.90
Bid29.26 x 3100
Ask29.80 x 800
Day's Range28.90 - 29.31
52 Week Range20.09 - 33.00
Volume278,350
Avg. Volume387,314
Market Cap1.194B
Beta1.34
PE Ratio (TTM)N/A
EPS (TTM)-1.94
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Retrophin to Present at Upcoming Investor Conferences

    SAN DIEGO, Sept. 17, 2018-- Retrophin, Inc. today announced that the Company’ s management team will present at the following upcoming investor conferences in October:. Cantor Global Healthcare Conference ...

  • GlobeNewswire14 days ago

    Retrophin Prices Upsized $240 Million Convertible Senior Notes Offering

    Retrophin, Inc. (RTRX) today announced the pricing of its offering of $240 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes”) to be sold in an underwritten offering. The aggregate principal amount of the offering was increased from the previously announced offering size of $200 million. Retrophin also granted the underwriters of the notes an option to purchase, for settlement on or before September 28, 2018, up to an additional $36 million aggregate principal amount of notes, solely to cover over-allotments.

  • Benzinga15 days ago

    The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Biotech Stocks Hitting 52-week highs on Sept. 4) Aptinyx Inc (NASDAQ: APTX ) Becton Dickinson and Co ...

  • GlobeNewswire15 days ago

    Retrophin Announces Proposed Convertible Senior Notes Offering

    Retrophin, Inc. (RTRX) today announced its intention to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in an underwritten offering. The notes will be senior unsecured obligations of Retrophin and will accrue interest payable semiannually in arrears. The notes will be convertible in certain circumstances into cash, shares of Retrophin’s common stock, or a combination of cash and shares of Retrophin’s common stock, at Retrophin’s election.

  • GlobeNewswirelast month

    New Research Coverage Highlights pdvWireless, Fortuna Silver Mines, Nordic American Tankers, Amarin, Himax Technologies, and Retrophin — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of pdvWireless, ...

  • The Wall Street Journallast month

    Martin Shkreli’s Former Lawyer Sentenced to 18 Months in Prison

    Evan Greebel, a former corporate lawyer found guilty last year for helping “Pharma Bro” Martin Shkreli defraud a publicly traded pharmaceutical company, was sentenced Friday by a federal judge in Brooklyn to 18 months in prison. Prosecutors from the Brooklyn U.S. Attorney’s office had sought no less than five years for Mr. Greebel, describing him as a “corrupt lawyer” who, as outside counsel to Retrophin Inc., abused his position as a lawyer to help Mr. Shkreli steal millions of dollars’ worth of cash and shares from the company to pay investors in Mr. Shkreli’s failed hedge funds. U.S. District Judge Kiyo A. Matsumoto said she believed Mr. Greebel was “personally generous and kind,” but said that he “abused his position of trust” and played an active role in the schemes.

  • Reuterslast month

    Ex-lawyer of pharma executive Shkreli gets 18 months prison for fraud scheme

    A New York lawyer was sentenced to 18 months prison on Friday for helping Martin Shkreli, currently serving a seven year prison sentence after being convicted of related charges, defraud a drug company that Shkreli had founded. Evan Greebel, who was outside counsel to Shkreli's former company Retrophin Inc (RTRX.O), was sentenced by U.S. District Judge Kiyo Matsumoto in Brooklyn. The judge also ordered Greebel to pay about $10.4 million in restitution to Retrophin.

  • Reuterslast month

    Ex-lawyer of pharma exec Shkreli gets 18 months prison for fraud scheme

    A New York lawyer was sentenced to 18 months prison on Friday for helping Martin Shkreli, currently serving a seven year prison sentence after being convicted of related charges, defraud a drug company that Shkreli had founded. Evan Greebel, who was outside counsel to Shkreli's former company Retrophin Inc, was sentenced by U.S. District Judge Kiyo Matsumoto in Brooklyn. The judge also ordered Greebel to pay about $10.4 million in restitution to Retrophin.

  • Martin Shkreli's Company Lawyer Sentenced to 18 Months for Fraud
    Bloomberglast month

    Martin Shkreli's Company Lawyer Sentenced to 18 Months for Fraud

    Martin Shkreli’s cohort in crime may be a "mensch" and an Eagle Scout who’s devoted his life to serving others, but that didn’t save Evan Greebel from a prison sentence for aiding the Pharma Bro in an $11 million fraud. Greebel on Friday was ordered to serve 18 months behind bars for conspiring with Shkreli, as U.S. District Judge Kiyo Matsumoto in Brooklyn, New York, turned aside his plea to remain free. "I will regret every day of my life the day that I met Martin Shkreli," Greebel told the judge.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RTRX earnings conference call or presentation 26-Jul-18 8:30pm GMT

    Q2 2018 Retrophin Inc Earnings Call

  • GlobeNewswire2 months ago

    Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

    Retrophin, Inc. (RTRX) today announced the appointment of Noah L. Rosenberg, M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline. Dr. Rosenberg brings to Retrophin more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization. “Noah’s expertise and career-long focus on therapeutic innovation and patient quality of care strengthens our leadership team and aligns seamlessly with our mission of identifying, developing and delivering life-changing therapies to people living with rare diseases,” said Stephen Aselage, chief executive officer of Retrophin.

  • GlobeNewswire2 months ago

    Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan

    Patients continue to enroll in Phase 3 FORT Study of fosmetpantotenate in PKAN and Phase 3 DUPLEX Study of sparsentan in FSGS. Phase 2 proof-of-concept study of CNSA-001 in patients with PKU set to initiate; ...

  • Benzinga2 months ago

    Retrophin Earnings Preview

    Retrophin (NASDAQ: RTRX ) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement. Earnings and Revenue Retrophin's per-share loss ...

  • GlobeNewswire2 months ago

    Retrophin to Report Second Quarter 2018 Financial Results

    SAN DIEGO, July 12, 2018-- Retrophin, Inc. today announced it will report second quarter 2018 financial results on Thursday, July 26, 2018 after the close of the U.S. financial markets. The Company will ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of RTRX earnings conference call or presentation 1-May-18 8:30pm GMT

    Q1 2018 Retrophin Inc Earnings Call

  • Associated Press5 months ago

    Retrophin: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 46 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 14 cents per share. The drug developer posted revenue of ...

  • CNBC5 months ago

    Fight brews over Shkreli's Wu-Tang album as 'pharma bro' gets banned by securities industry

    New York's attorney general said state tax authorities are entitled to first dibs on more than $480,000 out of the nearly $7.4 million Shkreli was ordered to forfeit to the federal government as regulators ...

  • Shkreli arrives at low-security prison in New Jersey
    American City Business Journals5 months ago

    Shkreli arrives at low-security prison in New Jersey

    "Pharma bro" had requested to be sent to Pennsylvania-based Camp Canaan.